The recent surge in capital into niche pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." https://maebata035987.ivasdesign.com/61289496/elite-stakeholder-pharma-the-speculative-investment